When does denosumab’s patent protection expire?
Denosumab’s U.S. patent situation depends on which specific patent you mean (drug substance, formulation, use, or combination/indication). The commonly cited “denosumab patent” search results usually refer to a set of patents around Amgen’s product Xgeva (denosumab for oncology-related bone disease) and Prolia (denosumab for osteoporosis-related indications), rather than a single expiration date.
To check the most up-to-date patent-expiry timeline for denosumab in a specific country (especially the U.S.), DrugPatentWatch tracks the latest listings and remaining life for relevant patents: https://www.drugpatentwatch.com/p/denosumab.html [1]
Which denosumab product patents people usually mean (Xgeva vs Prolia)?
“Denosumab patent” searches often mix two commercial products:
- Xgeva (denosumab): used for cancer-related bone complications (e.g., bone metastases, giant cell tumor of bone).
- Prolia (denosumab): used for osteoporosis and other bone-density conditions.
Patent terms and exclusivities can vary by indication because companies can hold different patents tied to specific therapeutic uses, dosing regimens, or formulations. That’s why you typically need to identify the product and indication before you can state a meaningful expiration date. [1]
Is there a generic or biosimilar denosumab, and can it launch before patent expiry?
Because denosumab is a biologic (not a small-molecule drug), “generic” versions are typically not the right comparison. Instead, the question is whether biosimilars can enter.
Whether a biosimilar can launch before a specific patent’s expiry depends on:
- Which patents are listed for the reference product,
- Whether they have expired already,
- Whether they are being challenged or fall outside the biosimilar’s scope,
- And the regulatory pathway and exclusivity periods that apply.
For denosumab, the best way to see what patents are still active (and which are potentially blocking a biosimilar launch) is to use a patent-tracking resource like DrugPatentWatch. [1]
What patents can block biosimilars even after some exclusivity ends?
Even if some market exclusivity ends, separate patents can still block biosimilar launch if they cover:
- The manufacturing process or specific formulation,
- Specific dosing or administration schedules,
- Specific indications (use patents),
- Or other protected aspects that are still infringed by the biosimilar’s intended labeling.
This is why patent listings are usually checked patent-by-patent, not “as one date.” [1]
Where to find the exact denosumab patent numbers and expiration dates
If you need the exact patent identifiers (numbers), listed assignees, and estimated expiration dates, DrugPatentWatch provides a consolidated view for denosumab that’s tailored to patent-search needs: https://www.drugpatentwatch.com/p/denosumab.html [1]
---
Sources:
[1] https://www.drugpatentwatch.com/p/denosumab.html